|77.77||+0.6600||+0.86%||Vol 863.37K||1Y Perf -6.29%|
|Apr 13th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||106.25||Analyst Rating||Strong Buy 1.38|
|Potential %||36.62||Finscreener Ranking||★★★★★ 62.24|
|Insiders Trans % 3/6/12 mo.||-100/-100/-79||Value Ranking||★★★★+ 59.56|
|Insiders Value % 3/6/12 mo.||-100/-100/-91||Growth Ranking||★★★★★ 82.49|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-88||Income Ranking||— -|
|Market Cap||14.14B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||10.59||Earnings Date||5th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2021|
|Estimated EPS Next Report||0.06|
|EPS Growth Next 5 Years %||31.70|
|Avg. Weekly Volume||827.10K|
|Avg. Monthly Volume||1.07M|
|Avg. Quarterly Volume||1.20M|
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock closed at 77.77 per share at the end of the most recent trading day (a 0.86% change compared to the prior day closing price) with a volume of 863.49K shares and market capitalization of 14.14B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3059 people. BioMarin Pharmaceutical Inc. CEO is Jean-Jacques Bienaime.
The one-year performance of BioMarin Pharmaceutical Inc. stock is -6.29%, while year-to-date (YTD) performance is -11.31%. BMRN stock has a five-year performance of -12.47%. Its 52-week range is between 71.35 and 131.95, which gives BMRN stock a 52-week price range ratio of 10.59%
BioMarin Pharmaceutical Inc. currently has a PE ratio of 17.70, a price-to-book (PB) ratio of 3.46, a price-to-sale (PS) ratio of 10.32, a price to cashflow ratio of 175.70, a PEG ratio of 2.32, a ROA of 15.69%, a ROC of 18.21% and a ROE of 22.89%. The company’s profit margin is 58.96%, its EBITDA margin is 5.00%, and its revenue ttm is $1.36 Billion , which makes it $7.47 revenue per share.
Of the last four earnings reports from BioMarin Pharmaceutical Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.06 for the next earnings report. BioMarin Pharmaceutical Inc.’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for BioMarin Pharmaceutical Inc. is Strong Buy (1.38), with a target price of $106.25, which is +36.62% compared to the current price. The earnings rating for BioMarin Pharmaceutical Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioMarin Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioMarin Pharmaceutical Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 14.79, ATR14 : 2.92, CCI20 : 29.49, Chaikin Money Flow : -0.03, MACD : -1.94, Money Flow Index : 46.67, ROC : 4.03, RSI : 45.43, STOCH (14,3) : 70.62, STOCH RSI : 1.00, UO : 43.50, Williams %R : -29.38), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioMarin Pharmaceutical Inc. in the last 12-months were: David E.I. Pyott (Buy at a value of $2 003 430), Elaine J. Heron (Sold 0 shares of value $-794 700 ), G. Eric Davis (Sold 12 504 shares of value $1 117 607 ), Henry J. Fuchs (Sold 0 shares of value $-9 855 750 ), Henry J. Fuchs (Sold 186 613 shares of value $22 888 787 ), Jean-Jacques Bienaime (Sold 0 shares of value $-3 100 080 ), Jean-Jacques Bienaime (Sold 133 000 shares of value $11 836 194 ), Jeffrey R. Ajer (Sold 0 shares of value $-946 500 ), Jeffrey R. Ajer (Sold 21 262 shares of value $2 345 163 ), Michael G. Grey (Sold 0 shares of value $-264 900 ), Michael G. Grey (Sold 10 000 shares of value $983 150 ), V. Bryan Lawlis (Sold 0 shares of value $-198 675 ), V. Bryan Lawlis (Sold 16 360 shares of value $1 607 671 ), Willard H. Dere (Sold 8 860 shares of value $1 095 185 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.